Published in J Clin Oncol on January 03, 2006
Cytotoxic anticancer agents and renal impairment study: the challenge remains. J Clin Oncol (2006) 1.43
Role of the glutamate 185 residue in proton translocation mediated by the proton-coupled folate transporter SLC46A1. Am J Physiol Cell Physiol (2009) 1.33
Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs (2006) 1.29
Acute Tubular Necrosis and Interstitial Nephritis during Pemetrexed Therapy. Case Rep Oncol (2009) 1.04
Identification of Tyr residues that enhance folate substrate binding and constrain oscillation of the proton-coupled folate transporter (PCFT-SLC46A1). Am J Physiol Cell Physiol (2015) 0.82
Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. Invest New Drugs (2008) 0.81
An epigenetic mechanism for capecitabine resistance in mesothelioma. Biochem Biophys Res Commun (2009) 0.80
Substrate- and pH-specific antifolate transport mediated by organic anion-transporting polypeptide 2B1 (OATP2B1-SLCO2B1). Mol Pharmacol (2011) 0.80
Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer (2014) 0.77
Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study. PLoS One (2017) 0.75
Effect of renal function on pemetrexed-induced haematotoxicity. Cancer Chemother Pharmacol (2016) 0.75
Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed. Mol Clin Oncol (2014) 0.75
Pemetrexed-Induced Nephrogenic Diabetes Insipidus. Am J Kidney Dis (2016) 0.75
A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function. Cancer Chemother Pharmacol (2016) 0.75
Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature. J Med Case Rep (2017) 0.75
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 24.87
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol (2009) 8.46
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 7.55
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA (2010) 5.78
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol (2004) 5.08
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol (2003) 4.07
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist (2009) 3.92
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A (2010) 3.86
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol (2006) 3.71
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol (2002) 3.53
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol (2011) 3.51
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol (2007) 3.37
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res (2012) 3.36
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol (2007) 2.93
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol (2009) 2.89
Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group. Clin Cancer Res (2008) 2.89
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst (2002) 2.84
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol (2008) 2.65
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol (2009) 2.63
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res (2007) 2.52
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol (2006) 2.48
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol (2011) 2.46
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol (2008) 2.35
Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res (2007) 2.30
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2009) 2.30
Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol (2005) 2.28
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol (2013) 2.27
Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol (2008) 2.24
Biostatistics primer: what a clinician ought to know: hazard ratios. J Thorac Oncol (2011) 2.15
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood (2007) 2.14
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol (2011) 2.10
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol (2010) 2.07
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res (2007) 2.07
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol (2012) 2.04
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol (2007) 2.01
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res (2009) 2.01
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res (2010) 1.96
The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol (2008) 1.94
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res (2013) 1.90
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood (2013) 1.87
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol (2006) 1.84
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol (2008) 1.84
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res (2003) 1.82
Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol (2013) 1.81
Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol (2003) 1.80
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol (2003) 1.79
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res (2006) 1.75
Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res (2009) 1.72
Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther (2012) 1.72
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol (2008) 1.71
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol (2007) 1.66
Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol (2005) 1.65
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol (2009) 1.64
Raf: a strategic target for therapeutic development against cancer. J Clin Oncol (2005) 1.63
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res (2006) 1.58
Barriers to the implementation of surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys (2012) 1.58
Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res (2008) 1.57
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res (2004) 1.55
Can tumor angiogenesis be inhibited without resistance? EXS (2005) 1.55
Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol (2004) 1.53
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer (2007) 1.52
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol (2011) 1.52
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol (2002) 1.52
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer (2007) 1.52
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther (2002) 1.51
A randomized survey of the preference of gastroenterologists for a Cochrane review versus a traditional narrative review. Can J Gastroenterol (2002) 1.49
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst (2006) 1.48
Interaction of imatinib with human organic ion carriers. Clin Cancer Res (2008) 1.47
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.47
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther (2007) 1.47
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res (2003) 1.42
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab (2008) 1.40
Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor. AJR Am J Roentgenol (2014) 1.39
Ductal access for prevention and therapy of mammary tumors. Cancer Res (2006) 1.38
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst (2006) 1.38